NeoX Biotech

Established in 2018 and based in Beijing, China, NeoX Biotech is a enterprise in the field of biopharmaceuticals. The company was founded by Dr. Hang Chen, who holds a Ph. D.

in physical chemistry from MIT and has a strong background in computational immunology. Dr. Chen's expertise is complemented by a multidisciplinary team with expertise in computational chemistry, biophysics, AI, immunology, oncology, and medicinal chemistry. The team includes researchers from prestigious institutions such as Peking University, the Max Planck Institute for Infection Biology, and Merck & Co.

NeoX Biotech has established strategic partnerships with global biomedical companies to accelerate drug R&D pipelines and has received recognition through awards such as the first place in the LEO Pharma Innovation Competition. In July 2021, it closed a round of series A+ funding. specializes in the research and development of macromolecular and multispecific drugs, particularly in the area of immuno-oncology. The company's neoPlatform technology integrates AI, computational biophysics, and high-throughput experimental data to drive the discovery of therapeutics, focusing on protein-protein interactions (PPIs).

This approach has been applied to various innovative drug modalities, including nanobodies, fusion proteins, bispecific antibodies, and protein degraders, aiming to develop "First-in-Class" or "Best-in-Class" drug products. The company generates revenue through the development and potential commercialization of its innovative drug pipeline, including partnerships and collaborations with pharmaceutical companies for drug discovery and development.